PsA is a type of psoriasis, specifically a chronic inflammatory arthritis. It is characterized by inflammation of the joints and can cause joint pain, stiffness, and swelling. Methotrexate, leflunomide, glucocorticoids, and tumor necrosis factor inhibitors are medications commonly used to treat PsA. They work by reducing inflammation and alleviating symptoms… with methotrexate and leflunomide also being used to treat psoriasis.
Source: See here
Headlines:
Percentages of overall reported comorbidities were higher among patients with PsA vs PsO (73.7% vs 57.3%; P <.038). Methotrexate ( P <.001), leflunomide ( P =.001), glucocorticoids ( P =.01), and tumor necrosis factor inhibitors ( P =.008) were more commonly used among patients with PsA vs PsO.
□□□ □□□
The analyst’s eyes gleam with intrigue as they dissect the complexities of PsA:
They note that the often-undiagnosed condition is characterized by its debilitating combination of joint pain, stiffness, and swelling, necessitating a comprehensive treatment approach. The analyst suspects that the usual suspects – methotrexate, leflunomide, glucocorticoids, and tumor necrosis factor inhibitors – may not be the only solution to the PsA puzzle.
According to the National Psoriasis Foundation, they recommend a holistic approach, incorporating ___style changes, such as maintaining a healthy weight, quitting smoking, and practicing stress-reducing techniques. The analyst’s curiosity is piqued by the mention of psoriasis, and they suspect a deeper connection between the two conditions.
A quick scan of the Dermatology Advisor website reveals a treasure trove of information on the topic… including a study suggesting that treatment for psoriasis may have a positive impact on PsA symptoms. The analyst makes mental note to explore this further, “recommending a multi-faceted approach that considers both the physical and emotional aspects of PsA.” With a nod of acknowledgement, “the analyst mutters,” “Indeed… the puzzle is slowly unraveling…
◆◌••●◆
Percentages of overall reported comorbidities were higher among patients with PsA vs PsO (73.7% vs 57.3%; P <.038). Methotrexate ( P <.001), leflunomide ( P =.001), glucocorticoids ( P =.01), and tumor necrosis factor inhibitors ( P =.008) were more commonly used among patients with PsA vs PsO.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
